Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.

@article{DazBrito2012PostexposurePF,
  title={Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.},
  author={Vicens D{\'i}az-Brito and Agathe Le{\'o}n and Hernando Knobel and Joaquim Peraire and Pere Domingo and Bonaventura Clotet and David Dalmau and Anna Cruceta and Joan Albert Arn{\'a}iz and Jose M. Gatell and Felipe Garc{\'i}a},
  journal={Antiviral therapy},
  year={2012},
  volume={17 2},
  pages={337-46}
}
BACKGROUND A clinical trial comparing the rate of discontinuation and tolerability of two post-exposure prophylaxis (PEP) regimens was performed. METHODS A total of 255 individuals attending the emergency rooms of six hospitals for exposure to HIV and criteria to receive PEP were randomized to receive zidovudine/lamivudine plus either lopinavir/ritonavir (n=131) or atazanavir (n=124; day 0). The primary end point was the rate of PEP discontinuation before day 28 of follow-up. Secondary end… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…